stemmacolore
Search

Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

Leucemia acuta linfoblastica Philadelphia-positiva dell’adulto alla diagnosi. Trattamento sequenziale con il ponatinib e l’anticorpo monoclonale bispecifico blinatumomab vs chemioterapia e imatinib.

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
GIMEMA ALL2820
Codice EudraCT
2020-006048-15
Sponsor/Promotore
FONDAZIONE G.I.M.EM.A (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) ONLUS
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator

Studio randomizzato, prospettico, sulla fattibilità del trapianto allogenico di cellule staminali in pazienti affetti da Sindrome mielodisplastica ad alto rischio, eseguito upfront o preceduto da azacitidina o chemioterapia convenzionale, secondo la percentuale di blasti midollari (studio ACROBAT)

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
MDS0519 (ACROBAT)
Codice EudraCT
2019-003997-25
Sponsor/Promotore
FONDAZIONE G.I.M.EM.A (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) ONLUS
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator

Studio osservazionale retrospettivo/prospettico per valutare le caratteristiche clinico biologiche e l’outcome di pazienti affetti da Leucemia Acuta afferenti ai Centri di Ematologia aderenti alla Rete Ematologica Veneta

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
REV-AL01
Codice EudraCT
NP
Sponsor/Promotore
Azienda ULSS 3 Serenissima- Ospedale dell'Angelo
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Studio di fase III per determinare l’impatto di gemtuzumab ozogamicin, in associazione a chemioterapia standard, sui livelli di malattia minima residua, e il ruolo di glasdegib come mantenimento post-trapianto, in pazienti adulti, di età compresa tra 18 e 60 anni, affetti da Leucemia Mieloide Acuta non precedentemente trattata, di nuova diagnosi, a rischio favorevole o intermedio

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
GIMEMA AML1819
Codice EudraCT
2019-003871-20
Sponsor/Promotore
FONDAZIONE G.I.M.EM.A (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) ONLUS
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top